Abstract
There is no clinically significant increased risk of COVID-19 diagnosis or hospitalization with ACE or ARB use. Users should not discontinue or change their treatment to avoid COVID-19.
Introduction
Early in the COVID-19 pandemic, a biological hypothesis suggested that drugs interacting with the Renin-Angiotensin System (RAS)—specifically Angiotensin-Converting Enzyme inhibitors (ACEs) and Angiotensin Receptor Blockers (ARBs)—might increase susceptibility to the SARS-CoV-2 virus. The concern was that these medications could upregulate ACE2 expression, the receptor used by the virus to enter human cells. Given the prevalence of hypertension and the widespread use of these drugs, clarifying this risk was a global health priority.
Methods
This study employed an open-science, federated cohort design to compare ACE/ARB users against patients taking other first-line antihypertensives, such as Calcium Channel Blockers (CCBs) and Thiazide Diuretics (THZs). This active comparator design helps mitigate "confounding by indication" by ensuring compared groups have similar underlying health profiles.
Key methodological components included:
- Large-Scale Propensity Score (PS) Adjustment: Regularized regression was used to balance cohorts across thousands of potential confounding variables (age, sex, comorbidities, etc.).
- Empirical Calibration: The researchers used 76 "negative control" outcomes to detect and adjust for systematic bias, providing a higher level of statistical confidence than nominal p-values.
- Federated Analytics: Using the OHDSI network and the OMOP Common Data Model, identical analysis code was executed across international databases without sharing sensitive patient-level data.
Datasets
The analysis utilized three major electronic health record (EHR) and claims databases, encompassing over 1.1 million antihypertensive users:
- SIDIAP (Spain): Primary care records covering ~80% of Catalonia's population.
- CUIMC (USA): EHR data from Columbia University Irving Medical Center in New York.
- VA-OMOP (USA): Data from the US Department of Veterans Affairs, covering millions of veterans across 170 medical centers.
Results
The study found no evidence that ACE or ARB use increases the risk of COVID-19 infection or severe outcomes.
- Infection Risk: The meta-analytic Hazard Ratio (HR) for COVID-19 diagnosis comparing ACE/ARB users to CCB/THZ users was 0.98 (95% CI 0.84 - 1.14), indicating no significant difference.
- Disease Severity: No significant differences were observed regarding COVID-19-related hospitalization or pneumonia.
- ACE vs. ARB: Direct comparison showed a marginally lower risk of diagnosis for ACE users (HR 0.88), though this was inconsistent across outcomes and likely reflects residual bias rather than a true clinical advantage.
Discussion and Conclusion
While the "ACE2 upregulation" theory was biologically plausible in laboratory settings, this large-scale study demonstrates it does not translate into clinical risk for patients. The consistency of results across diverse healthcare systems in Spain and the US reinforces the generalizability of these findings.
Clinical guidelines advising patients to continue their hypertension treatments during the pandemic are strongly supported by this evidence. Future research may still explore the basic biological mechanisms of RAS therapy on tissue-specific ACE2 expression, but the clinical question of susceptibility appears resolved.
Summary updated